Wnt3a 转基因基质细胞的建立及其对脐血CD34+ 造血干/祖细胞扩增作用的研究

Wnt 信号通路在造血干/祖细胞自我更新的过程中发挥至关重要的作用 . 纯化的 Wnt3a 蛋白可以实现造血干/祖细胞的扩增 . 通过病毒转染原代小鼠骨髓基质细胞,建立转基因滋养层细胞 . 通过共培养对转基因滋养层细胞扩增 CD34+ 造血干/祖细胞的作用进行了研究 . 实验结果显示 , 与普通滋养层加细胞因子组相比,经转基因滋养层加细胞因子组培养的 CD34+造血干/祖细胞集落形成能力 (CFC) 是其 (1.55±0.06) 倍;混合集落形成能力是其 (1.95±0.26) 倍;高增殖潜能集落形成能力 (HPP-CFC) 是其 (1.45±0.40) 倍; LTC-IC 活性是其 (3.83±0.86) 倍 . 结果表明,转基因滋养层细胞通过分泌具有天然活性的 Wnt3a 蛋白能在体外有效地扩增造血干/祖细胞的数量 .     

一种新型生物反应器在造血干/祖细胞体外扩增中的应用

针对造血干/祖细胞体外扩增对培养环境的需求, 结合静/动态培养的特点, 开发了一种新型的生物反应器用于造血干/祖细胞的体外扩增.在该生物反应器内, 采用SCF TPO Flt-3细胞因子组合, 比较了静态和循环培养两种方式体外扩增脐血CD34 细胞的效果.培养7 d后, 总细胞分别扩增了(13.86 ± 4.26)和(7.23 ± 2.67)倍, 显示静态培养有利于总细胞的扩增; CD34 细胞扩增倍数、培养物中CD34 细胞含量均相近, 无显著性差异; 而CD34 CD38-细胞扩增倍数以及培养物中CD34 CD38-细胞的百分含量分别为(1.82 ± 0.58)和(3.90 ± 0.85)倍以及(9.45 ± 4.85)和(37.47 ± 14.06)%, 循环培养明显高于静态培养.可见, 在该生物反应器内, 采用静态和循环两种培养方式, 均能实现造血干/祖细胞的体外扩增, 但静态培养促使造血干细胞向定向祖细胞分化, 而循环培养则更有利于早期造血干细胞的扩增.     

用差异显示法分析不同生长环境中的造血干细胞/祖细胞基因表达的初步研究

对比分析不同生长环境中的脐血CD34+造血干/祖细胞基因表达变化。方法: 采用静态和动态培养系统培养脐血单个核细胞,1周后收获CD34+造血干/祖细胞, 提取总RNA, 用差异显示法对比分析在不同生长环境中造血干/祖细胞基因表达的差异。 结果: 在所使用的差异显示条件下,得到30个差异表达基因片段,其中一个差异表达片段为RAN基因,该基因属于RAS癌基因家族,可能与造血细胞增殖有关。结论: 不同生长环境影响CD34+造血干/祖细胞的基因表达,这些差异表达的基因可为优化体外培养环境,扩增造血细胞提供分子基础。     

一种新型生物反应器在造血干/祖细胞体外扩增中的应用

针对造血干/祖细胞体外扩增对培养环境的需求, 结合静/动态培养的特点, 开发了一种新型的生物反应器用于造血干/祖细胞的体外扩增。在该生物反应器内, 采用SCF+TPO+Flt-3细胞因子组合, 比较了静态和循环培养两种方式体外扩增脐血CD34+细胞的效果。培养7 d后, 总细胞分别扩增了(13.86 ± 4.26)和(7.23 ± 2.67)倍, 显示静态培养有利于总细胞的扩增; CD34+细胞扩增倍数、培养物中CD34+细胞含量均相近, 无显著性差异; 而CD34+CD38-细胞扩增倍数以及培养物中CD34+CD38?细胞的百分含量分别为(1.82 ± 0.58)和(3.90 ± 0.85)倍以及(9.45 ± 4.85)和(37.47 ± 14.06)%, 循环培养明显高于静态培养。可见, 在该生物反应器内, 采用静态和循环两种培养方式, 均能实现造血干/祖细胞的体外扩增, 但静态培养促使造血干细胞向定向祖细胞分化, 而循环培养则更有利于早期造血干细胞的扩增。     

造血干／祖细胞的基因转移

近年来发展的造血干／祖细胞基因转移技术被广泛用于血液遗传病的体细胞基因治疗研究。ＣＤ３４＾＋造血细胞含有高比例的原始造血干／祖细胞,是血液遗传病基因治疗的最佳受体细胞。以反转录病毒、腺相关病毒基因组为骨架构建的病功体因其高度感染特性而成为造血干／祖细胞基因转移的常用载体。随着珠蛋白基因表达调控规律的逐步阐明,人们已开始对人类最常见的血液遗传病－地中海贫血进行基因治疗的探索。     

GST-hDSL重组蛋白的原核表达纯化及对人造血祖细胞的扩增作用

目的:原核表达DSL与谷胱甘肽S转移酶(GST)的融合蛋白并研究观察GST-hDSL对人脐带血CD34 造血祖细胞的体外扩增作用.方法:将人DSL cDNA的蛋白编码序列克隆入原核表达载体pGEX-2T中,在大肠杆菌DH5α中诱导表达融合蛋白,用DEAE阴离子交换柱纯化目的蛋白.然后分离、纯化脐带血CD34 造血祖细胞,不加细胞因子或加入SCF(干细胞生长因子,stem cell factor)和GM-CSF(粒-巨噬细胞集落刺激因子,granuloeyte-macrophage colony-stimulating factor),经过14天的培养,检测GST-hDSL对细胞总数、CD34 细胞百分率、以及集落形成的影响.结果:当SCF和GM-CSF存在时,GST-hDSL组的CD34 细胞百分率,集落(colony forming cells,CFC)数以及高增值潜能集落(high proliferative potential colony forming cells,HPP-CFC)数分别是时照组的1.9、1.2、5.3倍.结论:当与SCF和GM-CSF联合作用时,重组GST-hDSL蛋白对造血祖细胞具有扩增作用.     

具有维持造血干/祖细胞能力的新型豆类凝集素的分离、纯化及功能鉴定

一种分离自豆类的新型凝集素不仅具有凝集活性,还具有体外长期维持造血干/祖细胞的能力.由眉豆（Dolichos lablab）中分离得到了这种多亚基的凝集素——FRIL（Flt3 receptor-interacting lectin）,并对它进行了核酸和蛋白质序列分析.免疫细胞分析显示,它的受体是CD34⁺造血干/祖细胞所特有的.在培养基中添加这种凝集素可长期维持CD34⁺细胞存活和增殖能力.以Flt3配基（FL）作为对照,在28天的培养时间内,相对于FL,FRIL可维持细胞较高的G0/G1期比例（80%以上G0/G1期）和长期培养中（14天以上）1.5倍以上的集落形成量.可见FRIL通过滞留造血干/祖细胞于G0/G1期而维持它们的自我更新潜能.     

ERK信号通路在人胚胎干细胞造血分化中的作用研究

细胞外调节蛋白激酶(extracellular regulated protein kinase,ERK)信号通路在斑马鱼及小鼠造血发生中发挥着重要作用,但其在人胚胎干细胞(human embryonic stem cells,h ESCs)造血分化中的作用尚不清楚。该研究利用h ESCs单层造血分化模型及ERK信号通路抑制剂PD98059探索了ERK信号通路在h ESCs造血分化中的作用。采用免疫荧光技术、流式细胞术分析发现,PD98059能够显著抑制CD43~+造血干/祖细胞的产生。进一步的研究发现,PD98059的作用阶段为APLNR+侧板中胚层产生阶段,在该作用阶段添加PD98059与造血分化全程添加对CD43~+造血干/祖细胞产生的抑制效果一致。该研究结果表明,抑制ERK信号通路通过抑制侧板中胚层细胞的产生而抑制h ESCs造血分化。该研究为建立体外h ESCs高效造血分化体系及规模化产生功能性血细胞奠定了理论基础。     

组胺受体介导的造血和免疫调控

造血干／祖细胞及白细胞,血小板上均存在组胺H1和H2受体,造血细胞既可在造血生长因子刺激下合成组胺,也可从胞外空间摄取组胺,组胺在造血调控中通过其受体发挥第二信使作用,组胺受体对正常造血与异常造血具有不同的调控机制,激动组胺H2受体可支持正常造血并抑制恶性造血,同时单核巨噬细胞膜上H2受体的激动可有效地抑制ROS的产生,从而逆转ROS对NK细胞活性的抑制,组胺协同IL－2或IFN－α可高效激活NK细胞功能。     

干/祖细胞、造血干/祖细胞及造血干/祖细胞移植

干／祖细胞的研究是当前的热门课题,造血干／祖细胞移植已应用于临床。主要介绍干／祖细胞,造血干／祖细胞的基本概念和造血干／祖细胞移植的大致状况。     

人造血干/祖细胞多态性的研究:Ⅲ.骨髓CD34~ 造血干/祖细胞功能亚群的分析

CD 34~ 造血干/祖细胞(HSC/HPC)是十分异质性的,由多个不同功能亚群所构成,在分化方向与重建造血等方面差异显著。本文对正常人骨髓CD 34~ HSC/HPC各亚群进行了较全面的分析。首先以阳性选择策略,采用Isolex~(TM) 50免疫磁球分选术富集骨髓CD 34~ HSC/HPC,其纯度>90%,随之采用免疫荧光抗体双标记二维流式细胞仪对其测定,发现高纯度的CD 34~ HSC/HPC可分为八个不同亚群:1.CD 34~ /CD 71~-(23.4%—56.6%)与CD 34~ /CD 71~ (33.4%—66.6%);2.CD34~ /CD 45~-(80.8%—82.5%)与CD34~ /CD 45~ (8.1%—11.2%);3.CD 34~ /CD 33~-(20.4%—80.6%)与CD 34~ /CD 33~ (14.6%—64.8%);4.CD 34~ /DR~-(6.3%—11.0%)与CD 34~ /DR~ (82.8%—85.5%)。用免疫胶体金——免疫桥酶联组化双染色对上述亚群进一步分析的结果与流式细胞仪的高度一致,为研究各亚群的功能与生物学特性提供了坚实基础     

Expression of CD34 in hematopoietic cancer cell lines reflects tightly regulated stem/progenitor-like state

Hematopoietic cancer stem cells preserve cellular hierarchy in a manner similar to normal stem cells, yet the underlying regulatory mechanisms are poorly understood. It is known that both normal and malignant stem/progenitor cells express CD34. Here, we demonstrate that several cell lines (HL-60, U266) derived from hematopoietic malignancies contain not only CD34(-) but also CD34(+) subpopulations. The CD34(+) cells displayed a stem/progenitor-like phenotype since, in contrast to CD34(-) cells, they frequently underwent cellular division and rapidly formed colonies in methylcellulose-based medium. Strikingly, a constant fraction of the CD34(+) and CD34(-) cell subpopulations, when separated, rapidly switched their phenotype. Consequently, both separated fractions could generate tumors in immunocompromised NOD/LtSz-scid/scid mice. Cultures in vitro showed that the proportion of CD34(+) stem/progenitor-like cells in the population was decreased by cell-cell contact and increased by soluble factors secreted by the cells. Using cytokine arrays, we identified some of these factors, notably thymopoietin that was able to increase the proportion of CD34(+) cells and overall colony-forming capacity in tested cell lines. This action of thymopoietin was conserved in mononuclear cells from bone marrow. Therefore, we propose that hematopoietic cancer cell lines containing subpopulations of CD34(+) cells can provide an in vitro model for studies of cancer stem/progenitor cells.     

Identification of endoglycan, a member of the CD34/podocalyxin family of sialomucins

CD34 and podocalyxin are structurally related sialomucins, which are expressed in multiple tissues including vascular endothelium and hematopoietic progenitors. These glycoproteins have been proposed to be involved in processes as diverse as glomerular filtration, inhibition of stem cell differentiation, and leukocyte-endothelial adhesion. Using homologies present in the cytoplasmic tails of these proteins, we have identified a novel member of this family, which we designate endoglycan. This protein shares a similar overall domain structure with the other family members including a sialomucin domain, but also possesses an extremely acidic amino-terminal region. In addition, endoglycan contains several potential glycosaminoglycan attachment sites and is modified with chondroitin sulfate. Endoglycan mRNA and protein were detected in both endothelial cells and CD34(+) bone marrow cells. Thus, CD34, podocalyxin, and endoglycan comprise a family of sialomucins sharing both structural similarity and sequence homology, which are expressed by both endothelium and multipotent hematopoietic progenitors. While the members of this family may perform overlapping functions at these sites, the unique structural features of endoglycan suggest distinct functions for this molecule.     

MERP1: a mammalian ependymin-related protein gene differentially expressed in hematopoietic cells

We have utilized differential display polymerase chain reaction to investigate the gene expression of hematopoietic progenitor cells from adult bone marrow and umbilical cord blood. A differentially expressed gene was identified in CD34+ hematopoietic progenitor cells, with low expression in CD34- cells. We have obtained the full coding sequence of this gene which we designated human mammalian ependymin-related protein 1 (MERP1). Expression of MERP1 was found in a variety of normal human tissues, and is 4- and 10-fold higher in adult bone marrow and umbilical cord blood CD34+ cells, respectively, compared to CD34- cells. Additionally, MERP1 expression in a hematopoietic stem cell enriched population was down-regulated with proliferation and differentiation. Conceptual translation of the MERP1 open reading frame reveals significant homology to two families of glycoprotein calcium-dependant cell adhesion molecules: ependymins and protocadherins.     

Mesenchymal stem cells support expansion of in vitro irradiated CD34(+) cells in the presence of SCF, FLT3 ligand, TPO and IL3: potential application to autologous cell therapy in accidentally irradiated victims

Ex vivo expansion of residual autologous hematopoietic stem and progenitor cells collected from victims soon after accidental irradiation (autologous cell therapy) may represent an additional or alternative approach to cytokine therapy or allogeneic transplantation. Peripheral blood CD34+ cells could be a useful source of cells for this process provided that collection and ex vivo expansion of hematopoietic stem and progenitor cells could be optimized. Here we investigated whether mesenchymal stem cells could sustain culture of irradiated peripheral blood CD34+ cells. In vitro irradiated (4 Gy 60Co gamma rays) or nonirradiated mobilized peripheral blood CD34+ cells from baboons were cultured for 7 days in a serum-free medium supplemented with stem cell factor+thrombopoietin+interleukin 3+FLT3 ligand (50 ng/ml each) in the presence or absence of mesenchymal stem cells. In contrast to cultures without mesenchymal stem cells, irradiated CD34+ cells cultured with mesenchymal stem cells displayed cell amplification, i.e. CD34+ (4.9-fold), CD34++ (3.8-fold), CD34++/Thy-1+ (8.1-fold), CD41+ (12.4-fold) and MPO+ (50.6-fold), although at lower levels than in nonirradiated CD34+ cells. Fourteen times more clonogenic cells, especially BFU-E, were preserved when irradiated cells were cultured on mesenchymal stem cells. Moreover, we showed that the effect of mesenchymal stem cells is related mainly to the reduction of apoptosis and involves cell-cell contact rather than production of soluble factor(s). This experimental model suggests that mesenchymal stem cells could provide a crucial tool for autologous cell therapy applied to accidentally irradiated victims.